Profil
Nick Buffinger worked as Vice President-Corporate Development & IP Strategy at Surface Oncology, Inc. from 2014 to 2018.
He holds a doctorate degree from Stanford University School of Medicine and a graduate degree from The Santa Clara University School of Law.
Anciens postes connus de Nick Buffinger
| Sociétés | Poste | Fin |
|---|---|---|
| SURFACE ONCOLOGY, INC. | Corporate Officer/Principal | 01/05/2018 |
Formation de Nick Buffinger
| Stanford University School of Medicine | Doctorate Degree |
| The Santa Clara University School of Law | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Surface Oncology, Inc.
 Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
